Grifols bags Xembify FDA approval for primary immunodeficiencies
Xembify FDA approval : Spanish pharma company Grifols has been granted approval from the US Food and Drug Administration (FDA) for Xembify (immune globulin subcutaneous, human- klhw), the company’s 20% subcutaneous immunoglobulin solution, for the treatment of primary immunodeficiencies. The FDA approval for Xembify to be subcutaneously injected for the treatment of primary humoral immunodeficiency […]